Ona Therapeutics continued to build its ADC-focused obesity-adjacent strategy?—no, this cluster should be obesity funding—actually the market signal here is biotech venture capital. Multiple finance items in the feed pointed to active fundraising and late-stage deal flow. Notably, Ona raised $86.6 million in a venture round to advance ADC programs in breast cancer, while additional finance commentary highlighted sustained biopharma funding totals in early 2026. The combination points to investors prioritizing differentiated modalities and clinical momentum even as individual companies face clinical or regulatory uncertainty. For biotech operators, the key takeaway is that capital remains available for compelling assets and that underwriting continues to reward platform differentiation and near-term development milestones.